Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas

• Status: Unknown status
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to preliminarily evaluate the safety and efficacy of cabergoline combined hydroxychloroquine/chloroquine(HCQ/CQ) therapy for cabergoline-Resistant Prolactinomas

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhebao Wu
• Collaborators: Beijing Tiantan Hospital; Chinese PLA General Hospital; First Affiliated Hospital of Fujian Medical University; First Affiliated Hospital of Wenzhou Medical University; First Hospital of China Medical University; Huashan Hospital; Peking Union Medical College Hospital; Xinqiao Hospital of Chongqing
• Treatments: Cabergoline; Chloroquine; Chloroquine diphosphate; Hydroxychloroquine

Criteria

Inclusion Criteria:

1. Aged between 18 and 70 years old, either sex;

2. Karnofsky performance status ≥ 70;

3. Patients who were suffered drug-resistant,which has taken cabergoline ≥2.0mg/week no less than 3 months, referring to failure to normalize PRL levels and failure to decrease macroprolactinoma size by >or=50%;

4. The patient has signed the informed consent.

Exclusion Criteria:

1. Patients concomitantly taking the psychotropic drugs or other drugs causing elevated PRL ;

2. Patients with parkinson disease and is taking dopaminergic agents;

3. Patients with prolactinoma who received Gamma knife treatment;

4. Patients who use any dopamine receptor agonists other than cabergoline;

5. pregnant or lactating women, or women preparing pregnant;

6. Patients with poor compliance, who cannot implement the program strictly.

7. History of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQ.

8. Glucose-6-phosphate dehydrogenase (G6PD) deficiency, as HCQ may cause hemolytic anemia in patients with G6PD deficiency.